Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.58 |
| ▸ | NPY1R | P25929 | 8/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.58 |
| ▸ | NPY2R | P49146 | 6/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13388431 | 0.93 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RNPBWR1 | |
| SCHEMBL12510278 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RNPBWR1 | |
| SCHEMBL30179308 | 0.86 | TFPI (0.48) | NPBWR1IL23RTFPINMUR2NMUR1 | |
| SCHEMBL30179150 | 0.86 | TFPI (0.48) | NPBWR1IL23RTFPINMUR2NMUR1 | |
| SCHEMBL30179445 | 0.86 | TFPI (0.48) | NPBWR1IL23RTFPINMUR2NMUR1 | |
| SCHEMBL30179352 | 0.86 | TFPI (0.48) | NPBWR1IL23RTFPINMUR2NMUR1 | |
| SCHEMBL12727966 | 0.84 | TFPI (0.56) | NPY4RNPY1RNPY5RNPY2RIL23R | |
| SCHEMBL31735160 | 0.82 | OPRD1 (0.54) | NPY4RNPY1RNPY5RNPY2RCHRNA1 | |
| SCHEMBL24668332 | 0.81 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RNPBWR1 | |
| SCHEMBL23384363 | 0.81 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691813-B2 | Provided are lactam-cyclized peptide CXCR4 antagonists (g-coupled protein receptor inhibitors) and a ligand SDF-1 (stromal cell-derived factor-1) useful in the in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection | ELI LILLY AND COMPANY (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2008150689-A1 | CYCLIC PEPTIDE CXCR4 ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300177-A1 | CYCLIC PEPTIDE CXCR4 ANTAGONISTS | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300177-A1 | CYCLIC PEPTIDE CXCR4 ANTAGONISTS | CXCR4, CXCR1, CXCL12 | NPY4R 532/4885NPY1R 456/4885NPY5R 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.